Your browser doesn't support javascript.
loading
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
Balar, Arjun V; Kamat, Ashish M; Kulkarni, Girish S; Uchio, Edward M; Boormans, Joost L; Roumiguié, Mathieu; Krieger, Laurence E M; Singer, Eric A; Bajorin, Dean F; Grivas, Petros; Seo, Ho Kyung; Nishiyama, Hiroyuki; Konety, Badrinath R; Li, Haojie; Nam, Kijoeng; Kapadia, Ekta; Frenkl, Tara; de Wit, Ronald.
Affiliation
  • Balar AV; Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA. Electronic address: arjun.balar@nyulangone.org.
  • Kamat AM; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kulkarni GS; University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Uchio EM; University of California Irvine Health, Orange, CA, USA.
  • Boormans JL; Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands.
  • Roumiguié M; Institut Universitaire du Cancer Toulouse Oncopole CHU, Toulouse, France.
  • Krieger LEM; Genesis Care and Royal North Shore Hospital, Sydney, NSW, Australia.
  • Singer EA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Bajorin DF; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Grivas P; University of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Seo HK; National Cancer Center, Goyang, South Korea.
  • Nishiyama H; University of Tsukuba, Tsukuba, Ibaraki, Japan.
  • Konety BR; University of Minnesota, Minneapolis, MN, USA.
  • Li H; Merck & Co, Kenilworth, NJ, USA.
  • Nam K; Merck & Co, Kenilworth, NJ, USA.
  • Kapadia E; Merck & Co, Kenilworth, NJ, USA.
  • Frenkl T; Merck & Co, Kenilworth, NJ, USA.
  • de Wit R; Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands.
Lancet Oncol ; 22(7): 919-930, 2021 07.
Article in En | MEDLINE | ID: mdl-34051177
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / BCG Vaccine / Carcinoma in Situ / Carcinoma, Papillary / Antibodies, Monoclonal, Humanized / Antineoplastic Agents, Immunological / Immune Checkpoint Inhibitors Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2021 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / BCG Vaccine / Carcinoma in Situ / Carcinoma, Papillary / Antibodies, Monoclonal, Humanized / Antineoplastic Agents, Immunological / Immune Checkpoint Inhibitors Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2021 Document type: Article